tiprankstipranks
Advertisement
Advertisement

CPRX Stock Latest News

Catalyst Pharma Patent Trial Against Hetero USA Delayed
Company AnnouncementsCatalyst Pharma Patent Trial Against Hetero USA Delayed
24d ago
8K
CPRX
Catalyst Pharmaceutical Partners Signals Confident Growth Path
PremiumCompany Announcements
Catalyst Pharmaceutical Partners Signals Confident Growth Path
1M ago
CPRX
Buy Rating on Catalyst Pharma Driven by Strong 2026 Growth Outlook and Favorable Firdapse Litigation Upside
PremiumRatings
Buy Rating on Catalyst Pharma Driven by Strong 2026 Growth Outlook and Favorable Firdapse Litigation Upside
1M ago
CPRX
Catalyst Pharmaceuticals price target raised to $35 from $33 at Citi
PremiumThe Fly
Catalyst Pharmaceuticals price target raised to $35 from $33 at Citi
1M ago
CPRX
Buy Rating on Catalyst Pharma Backed by Strong Growth, Underpenetrated LEMS Opportunity, and Rising Profitability Post-Royalty Roll-Off
PremiumRatings
Buy Rating on Catalyst Pharma Backed by Strong Growth, Underpenetrated LEMS Opportunity, and Rising Profitability Post-Royalty Roll-Off
1M ago
CPRX
Catalyst Pharma Posts Record 2025 Results, Raises 2026 Outlook
PremiumCompany AnnouncementsCatalyst Pharma Posts Record 2025 Results, Raises 2026 Outlook
2M ago
8K
CPRX
Catalyst Pharmaceuticals reports Q4 EPS 68c, consensus 50c
Premium
The Fly
Catalyst Pharmaceuticals reports Q4 EPS 68c, consensus 50c
2M ago
CPRX
Catalyst Pharmaceuticals sees FY26 revenue $615M-$645M, consensus $615.58M
Premium
The Fly
Catalyst Pharmaceuticals sees FY26 revenue $615M-$645M, consensus $615.58M
2M ago
CPRX
Is CPRX a Buy, Before Earnings?
PremiumPre-Earnings
Is CPRX a Buy, Before Earnings?
2M ago
CPRX
Catalyst Pharmaceuticals: Rare-Disease Buy-and-Build Strategy, Strong Launches, and Capital Flexibility Underpin Buy Rating
PremiumRatings
Catalyst Pharmaceuticals: Rare-Disease Buy-and-Build Strategy, Strong Launches, and Capital Flexibility Underpin Buy Rating
3M ago
CPRX
Catalyst Pharma Highlights Growth Strategy at J.P. Morgan Conference
PremiumCompany Announcements
Catalyst Pharma Highlights Growth Strategy at J.P. Morgan Conference
3M ago
8K
CPRX
Catalyst Pharmaceuticals Reports Strong Q3 2025 Earnings
PremiumCompany Announcements
Catalyst Pharmaceuticals Reports Strong Q3 2025 Earnings
5M ago
CPRX
Catalyst Pharma’s Strategic Growth and Market Positioning: A Promising Outlook
PremiumRatingsCatalyst Pharma’s Strategic Growth and Market Positioning: A Promising Outlook
5M ago
CPRX
Catalyst Pharmaceuticals price target raised to $33 from $32 at Oppenheimer
Premium
The Fly
Catalyst Pharmaceuticals price target raised to $33 from $32 at Oppenheimer
5M ago
CPRX
Catalyst Pharmaceuticals price target raised to $33 from $31 at Citi
Premium
The Fly
Catalyst Pharmaceuticals price target raised to $33 from $31 at Citi
5M ago
CPRX
Catalyst Pharmaceuticals Reports Strong Q3 2025 Results
PremiumCompany Announcements
Catalyst Pharmaceuticals Reports Strong Q3 2025 Results
5M ago
CPRX
Catalyst Pharmaceuticals reports Q3 EPS 68c, consensus 54c
PremiumThe Fly
Catalyst Pharmaceuticals reports Q3 EPS 68c, consensus 54c
5M ago
CPRX
Catalyst Pharma Reports Strong Q3 2025 Financial Results
PremiumCompany Announcements
Catalyst Pharma Reports Strong Q3 2025 Financial Results
5M ago
8K
CPRX
Is CPRX a Buy, Before Earnings?
PremiumPre-Earnings
Is CPRX a Buy, Before Earnings?
5M ago
CPRX
Catalyst Pharma Announces $200M Share Repurchase Program
PremiumCompany AnnouncementsCatalyst Pharma Announces $200M Share Repurchase Program
6M ago
8K
CPRX
Nike reports Q1 beat, U.S. takes 5% stake in Lithium Americas: Morning Buzz
Premium
The Fly
Nike reports Q1 beat, U.S. takes 5% stake in Lithium Americas: Morning Buzz
6M ago
F
AES
Catalyst Pharmaceuticals announces $200M share repurchase program
Premium
The Fly
Catalyst Pharmaceuticals announces $200M share repurchase program
6M ago
CPRX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >